Fulcrum Therapeutics reported positive 12-week data from the 20 mg dose cohort of its Phase 1b PIONEER trial of pociredir for sickle cell disease. The drug demonstrated robust fetal hemoglobin (HbF) induction with mean absolute HbF increasing by 12.2% (from 7.1% to 19.3%), 58% of patients achieving HbF levels ≥20%, and 58% reporting zero vaso-occlusive crises during treatment. The drug was generally well-tolerated with no treatment-related serious adverse events. Fulcrum plans to initiate a potential registration-enabling trial in the second half of 2026 pending FDA feedback.

The U.S. firmware signing platform market is projected to grow from $0.40B in 2025 to $1.39B by 2033, driven by increasing demand for secure device updates across IoT, automotive, medical, and industrial systems, with a 16.78% CAGR.

Fulcrum Therapeutics has priced a public offering of 11,851,853 common stock shares and pre-funded warrants, expecting to raise $175.0 million to fund research, development, and potential acquisitions.

Fulcrum Therapeutics reported positive Phase 1b trial results for pociredir, an oral medication for sickle cell disease, showing significant increases in fetal hemoglobin and promising safety profile at the 20 mg dose level.

Datanomix and Fulcrum announced a strategic partnership to integrate ERP and production monitoring technologies, enabling manufacturers to unify job planning, scheduling, and live production tracking with real-time insights.

Fulcrum Therapeutics granted 47,450 non-statutory stock options to new employees at $9.50 per share, with a ten-year term and four-year vesting schedule.

Fulcrum Therapeutics granted 35,000 non-statutory stock options to a new employee at $7.27 per share, with a ten-year term and four-year vesting schedule.

Fulcrum Therapeutics, a clinical-stage biopharmaceutical company, announced that it granted stock options to a new employee as an inducement to join the company.

Fulcrum Therapeutics, a clinical-stage biopharmaceutical company, will release its third quarter 2024 financial results and host a conference call and webcast on November 13, 2024.

Fulcrum Therapeutics, a clinical-stage biopharmaceutical company, announced that it granted stock options to two new employees as an inducement to join the company.

Biohaven's pipeline candidate, troriluzole, met the primary endpoint in a pivotal study for the treatment of spinocerebellar ataxia, a rare neurological disease. The study showed a 50-70% delay in disease progression compared to untreated patients.

Fulcrum Therapeutics, Inc. announced that its Phase 3 REACH trial evaluating losmapimod in patients with FSHD did not achieve its primary endpoint, causing a significant drop in the company's stock price.